Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8574248 | 0.73 | TSHR (0.42) | ALDH1A1TSHRHPGDMAPK1MEN1 | |
| SCHEMBL24670869 | 0.68 | TSHR (0.36) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL8612225 | 0.67 | TSHR (0.43) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL14099491 | 0.67 | EPHX2 (0.35) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL23210 | 0.65 | TSHR (0.77) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL651261 | 0.65 | TSHR (0.77) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL13913112 | 0.64 | — | — | |
| SCHEMBL13056648 | 0.63 | EPHX2 (0.48) | ALDH1A1TSHRHPGDMAPK1MEN1 | |
| Triethylene Glycol SCHEMBL28729900 | 0.63 | MEN1 (0.42) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL8404635 | 0.63 | GRIA1 (0.50) | ALDH1A1TSHRMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | ALDH1A1 4151/4885TSHR 4142/4885HPGD 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.